ReviewTherapeutic advances in neurological disorders2014
Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.
Review in Therapeutic advances in neurological disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Safety and efficacy of teriflunomide on clinical course, and laboratory findings in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis: a triple-blind study.Journal of neurology · 2025Trial
- Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive Disease.Molecules (Basel, Switzerland) · 2026Review
- Knowledge mapping of disease-modifying therapy (DMT) in multiple sclerosis (MS): A bibliometrics analysis.Heliyon · 2024Article
- ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine.Frontiers in oncology · 2021Review
- Review
- The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia.Journal of neuroimmunology · 2020Article
- Targeting the Redox Landscape in Cancer Therapy.Cancers · 2020Review
- Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis.Innovations in clinical neuroscience · 2019Article
- Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.International journal of physiology, pathophysiology and pharmacology · 2019Review
- Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?Auto- immunity highlights · 2018Review
- Experimental Autoimmune Encephalomyelitis (EAE) as Animal Models of Multiple Sclerosis (MS).Cold Spring Harbor perspectives in medicine · 2018Review
- Teriflunomide Modulates Vascular Permeability and Microglial Activation after Experimental Traumatic Brain Injury.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Tolerability and discontinuation rates in teriflunomide-treated patients. A real-world clinical experience.Neurosciences (Riyadh, Saudi Arabia) · 2018Article
- Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Review
- Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the Literature.Clinical pharmacokinetics · 2017Review
- From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.Current neuropharmacology · 2017Review
- Long-term evolution of multiple sclerosis disability in the treatment era.Annals of neurology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of novel oral agents are now approved for use in relapsing multiple sclerosis (MS). Among these agents, teriflunomide has shown promise with respect to clinical efficacy and safety in relapsing MS patients. In this review we aim to clarify the role of teriflunomide in the context of current and emerging MS treatment options by summarizing relevant points on the use of teriflunomide in MS, with a discussion of teriflunomide's pharmacologic properties, pivotal clinical trials, and safety and tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.